XML 39 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Sep. 30, 2015
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities
The following tables present the Company’s financial assets and liabilities measured on a recurring basis using the fair value hierarchy at September 30, 2015 and March 31, 2015 (in thousands):

Fair Value Measurements at
 
September 30, 2015
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
215,539

 
$

 
$

 
$
215,539

U.S. government and municipal obligations
34,084

 
92,156

 


126,240

Commercial paper

 
2,990

 


2,990

Corporate bonds
6,616

 

 


6,616

Derivative financial instruments

 
34

 


34

Contingently returnable consideration
$

 
$

 
$
19,125

 
$
19,125


$
256,239

 
$
95,180

 
$
19,125


$
370,544

LIABILITIES:

 

 



Contingent purchase consideration
$

 
$

 
$
(4,560
)

$
(4,560
)
Derivative financial instruments

 
(416
)
 


(416
)

$

 
$
(416
)
 
$
(4,560
)

$
(4,976
)

Fair Value Measurements at
 
March 31, 2015
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
104,893

 
$

 
$


$
104,893

U.S. government and municipal obligations
46,564

 
98,781

 


145,345

Commercial paper

 
5,095

 


5,095

Corporate bonds
9,524

 

 


9,524

Derivative financial instruments

 
15

 


15


$
160,981


$
103,891


$


$
264,872

LIABILITIES:

 

 



Contingent purchase consideration
$

 
$

 
$
(4,484
)

$
(4,484
)
Derivative financial instruments

 
(1,664
)
 


(1,664
)

$


$
(1,664
)

$
(4,484
)

$
(6,148
)
Schedule of Reconciliation of Changes in Fair Value of Level III Financial Assets
The following table sets forth a reconciliation of changes in the fair value of the Company’s Level 3 financial assets and liabilities for the six months ended September 30, 2015 (in thousands):

Contingent
Purchase
Consideration
 
Contingently Returnable Consideration
Balance at beginning of period
$
(4,484
)
 
$

Increase in fair value and accretion expense (included within research and development expense)
(76
)
 
 
Contingently returnable consideration
 
 
19,125

Balance at end of period
$
(4,560
)
 
$
19,125